Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A single institution experience

Tumori

Volumn 98, Issue 1, 2012, Pages 33-38

  Crivellari, Diana ^a   Spazzapan, Simon ^a   Lombardi, Davide ^a   Militello, Loredana ^a,b   Torrisi, Elena ^a,b   Russo, Alessia E ^a,b   Sorio, Roberto ^a   Talamini, Renato ^a   Miolo, Gianmaria ^a   Carli, Paolo ^a   Veronesi, Andrea ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Capecitabine; HER2 positive metastatic breast cancer; Lapatinib

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE PLUS LAPATINIB; LOPERAMIDE; OCTREOTIDE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HER2 PROTEIN, HUMAN; LAPATINIB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TAXOID; TUMOR MARKER;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84863189791     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800104     Document Type: Article

References (25)

1. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mamm Gland Biol Neoplasia, 6: 393-406, 2001.
2. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J, 16: 1647-1655, 1997. (Pubitemid 27151960)
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177-182, 1987. (Pubitemid 17231334)
4. Wolff AC, Hammond EH, Hayes DF, Schwartz JN: American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth receptor 2 testing in breast cancer. J Clin Oncol, 25: 118-145, 2007. (Pubitemid 350003059)
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783-792, 2001. (Pubitemid 32222155)
6. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol, 23: 4265-4274, 2005. (Pubitemid 46207001)
7. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 28: 92-98. 2010.
8. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol, 27: 1999-2006, 2009.
9. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733-2743, 2006. (Pubitemid 46021510)
10. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 112: 533-543, 2008.
11. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 28: 803-814, 2009.
12. Spazzapan S, Crivellari D, Tumolo S, Lombardi D, Magri MD, Russo AE, Scalone S, Talamini R, Miolo G, Veronesi A: Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2 positive metastatic breast cancer: A monoinstitutional experience. J Clin Oncol, 28: 15s (suppl; abstr 1082), 2010.
13. Capri G, Chang J, Chen S-C, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S: An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol, 21: 474-480, 2010.
14. Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD, Wong R: Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol, 14: 13-20, 2007.
15. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol, 22: 2918-2926, 2004. (Pubitemid 41079912)
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92: 205-216, 2000.
17. Huang Z, Brdlik C, Jin Pet, Shepard HM: A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther, 9: 97-110, 2009.
18. Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A: Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER-2 negative or unknown metastatic breast cancer. J Clin Oncol, 27: 3908-3915, 2009.
19. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol, 26: 5544-5552, 2008.
20. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast Cancer. J Clin Oncol, 27: 5538-5546, 2009.
21. Crown JP, Burris HA, Boyle F, Jones S, Koehler M, Newstat BO, Parikh R, Oliva C, Preston A, Byrne J, Chan S: Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat, 112: 317-325, 2008.
22. Crown JP, Burris HA, Jones S: Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). J Clin Oncol, 25: 38s, (suppl; abstract 1027), 2007.
23. Jones SF, Burris HA 3rd, Yardley DA: Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 8-11 (abstr 1069), 2004.
24. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS: Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc, 83: 679-686, 2008. (Pubitemid 351810568)
25. Crivellari D, Spazzapan S, Magri MD, Frustaci S, Talamini R, Scalone S, Torrisi E, Lombardi D, Miolo G, Veronesi A: Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience. J Clin Oncol, 28: 15s, (suppl; abstr 1145), 2010.